Kamada Ltd. (KMDA) Reaches New 1-Year High at $5.34
Kamada Ltd. (NASDAQ:KMDA)’s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $5.34 and last traded at $5.04, with a volume of 307,314 shares trading hands. The stock had previously closed at $4.53.
Several equities analysts have recently issued reports on KMDA shares. Zacks Investment Research lowered shares of Kamada from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. TheStreet cut shares of Kamada from a “hold” rating to a “sell” rating in a research report on Thursday, June 9th.
The company’s market cap is $178.45 million. The company’s 50 day moving average is $4.08 and its 200-day moving average is $3.88.
Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.04) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). The company earned $19.10 million during the quarter, compared to the consensus estimate of $18.50 million. Equities analysts predict that Kamada Ltd. will post ($0.11) earnings per share for the current fiscal year.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.